JP6669595B2 - Absorbent articles - Google Patents

Description

  The present invention relates to an absorbent article for menstrual absorption.

In absorbent articles such as sanitary napkins, for the purpose of improving leakproofness and design, the topsheet and absorbent are pressed and compressed on the topsheet side facing the wearer's skin. Provision of a formed leakage prevention groove is performed (for example, see Patent Document 1).
Such a leak-proof groove is generally formed in an annular shape so as to surround the periphery of the excretion spot portion which is arranged to face the liquid excretion portion of the wearer when worn, or extends vertically on both left and right sides of the excretion spot portion. In any case, when a continuous leak-proof groove is formed, the rigidity of the absorbent article is increased, and the fitting property is easily reduced.
Therefore, Patent Literature 1 proposes a technique in which a compressed groove is separated in a longitudinal direction. According to such a technique, since the leakage preventing groove can be bent between the short grooves, the flexibility of the absorbent article is improved.
However, menstrual blood excreted in the excretion spots tends to diffuse outward through the gap between short grooves in the leak-proof groove due to deformation of the sanitary napkin due to movement of the body, etc. The leak-proof performance may be reduced.

By the way, regarding the technology relating to the absorption performance of menstrual blood, a technology is known in which a fluid treatment agent that acts on blood is applied to an absorbent article to improve various performances of the absorbent article (for example, Patent Document 2). ~ Patent Document 4). Patent Document 2 discloses a menstrual zone including an absorbent pad containing a salt of a polyvalent ion. Patent Document 3 discloses a napkin containing a partially hydrated dicarboxylic anhydride copolymer or polycation as a blood gelling agent. Patent Document 4 proposes a personal care absorbent article containing a triblock polymer or polycation containing polypropylene oxide and polyethylene oxide as a fluid treatment material.
In addition, the present applicant has previously proposed an absorbent article containing a blood coagulant containing a water-soluble metal compound in an absorbent core (see Patent Document 5).

JP 2010-148719 A JP-B-38-17449 JP-A-57-153648 JP 2002-528232 A JP 2005-287997 A

However, in Patent Document 1, although the compressed groove overlaps in the width direction at the end portion separated in the longitudinal direction, in the separated portion, the absorbent article is easily broken at the portion when worn, and the amount of excretion is large. Sometimes leakage is easy to occur.
In addition, Patent Documents 2 and 5 do not disclose any configuration for improving the blood absorption rate or the amount of absorbed blood except for using a water-soluble metal compound as a blood coagulant. On the other hand, in the absorbent article described in Patent Literature 3, the form of the emboss is unknown, and the blood gelling agent is concentrated along the end of the embossed line or along the end thereof. The absorption performance of the absorber cannot be fully utilized. Further, in the technique of Patent Document 4, red blood cell clumps are trapped between the fibers of the nonwoven web, but it is difficult to continuously guarantee blood absorption by the mechanism. Further, Patent Documents 3 and 4 disclose that a fluid treatment agent containing a polycation can be used in an absorbent article, but in fact, only data on nonionic treatment materials are disclosed. Not. In addition, in these techniques, the absorption of blood into the absorber is hindered due to a decrease in liquid permeability due to blood aggregates at a portion of the absorbent article facing the excretion spot of the wearer, and the absorption of blood is prevented. It is also disadvantageous in that it takes much time and the amount of absorbed blood is reduced.
Further, Patent Documents 1 to 5 disclose nothing about using a blood modifying agent as a measure against a decrease in leakproofness due to peeling between a surface sheet and an absorber generated in a leakproof groove. Not.
Therefore, an object of the present invention is to provide an absorbent article in which the effect of improving the absorption performance by the hemagglutinating agent is more effectively expressed.

  An object of the present invention is to provide an absorbent article that can solve the problems of the related art.

  The present invention includes a liquid-permeable top sheet forming a skin-facing surface, a back sheet forming a non-skin-facing surface, and an absorber disposed between these two sheets, and a longitudinal direction along the front-back direction of the wearer. And an absorbent article for absorbing menstrual blood having a lateral direction perpendicular to the longitudinal direction, wherein the laterally leak-proof groove is provided on each of both sides of a longitudinal center line on the skin-facing surface. The groove has a configuration in which the plurality of short grooves in which the topsheet indents into the absorber have a configuration arranged in the longitudinal direction so as to have a gap between the short grooves, and the back surface is more rearward than the topsheet. The lower member disposed at a position close to the sheet contains a hemagglutinating agent, and the gap in the lateral leakage prevention groove or the vicinity of the inside of the gap in the lateral direction is provided with the hemagglutinating agent in the lower member. Providing an absorbent article that overlaps the part That.

  The absorptive article of the present invention is excellent in both fit and leakproofness.

FIG. 1 is a plan view of a sanitary napkin, which is a first embodiment of the absorbent article according to the present invention, viewed from the skin-facing surface side. FIG. 2 is a schematic sectional view taken along line II-II of FIG. FIGS. 3A and 3B are schematic plan views showing the positional relationship between the leakage preventing groove and the flocculant disposing portion in the sanitary napkin of the first embodiment. FIG. 3C is a diagram corresponding to FIG. 3B in another embodiment. FIG. 4 is a plan view of a sanitary napkin, which is a second embodiment of the absorbent article according to the present invention, as viewed from the skin-facing surface side.

Hereinafter, an absorbent article for menstrual absorption according to the present invention will be described based on preferred embodiments with reference to the drawings. Absorbent articles for menstrual absorption are included in sanitary products.
The sanitary napkin 1 (hereinafter, also referred to as “napkin 1”) according to the first embodiment of the present invention includes a liquid-permeable topsheet 2 forming a skin-facing surface, as shown in FIGS. A back sheet 3 forming a non-skin-facing surface and a liquid-retentive absorber 4 disposed between the two sheets 2 and 3 are provided. The top sheet 2, the absorber 4, and the back sheet 3 are integrated to form an absorbent main body 5. Side leak-proof sheets 6 are arranged on both sides of the absorbent body 5 in the longitudinal direction on the side of the topsheet 2. The side leak-proof sheet 6 has a free end 61 not joined to the topsheet 2 and a fixed end 62 joined to the topsheet 2, and in use, between the fixed end 62 and the free end 61. Are separated from the topsheet 2 to form leak-proof pockets (not shown) for preventing lateral leakage to the side. A non-skin-facing surface of the absorbent main body 5 is provided with a main body adhesive portion (not shown) used for fixing the shorts to the crotch portion. The napkin 1 has a pair of wings 7 on both sides in the vertical direction X. A surface of the pair of wings 7 on the back sheet 3 side is provided with a wing adhesive part (not shown) used for fixing the crotch part of the shorts to the non-skin-facing surface.

  As the top sheet 2, the back sheet 3, and the side leakage-preventing sheet 6, various kinds of substances conventionally used for absorbent articles such as sanitary napkins can be used without any particular limitation. For example, as the topsheet 2, a single-layer or multilayer nonwoven fabric, an apertured film, or the like can be used. The topsheet 2 may have unevenness having a solid or hollow convex portion on the skin-facing surface side, or may be one attached to an oil agent on the surface of the constituent fibers. As the back sheet 3, a resin film or a laminate of a resin film, a nonwoven fabric, and the like can be used. As the back sheet 3, a liquid-impermeable (including liquid-impermeable) or water-repellent material is used, and it is also preferable to use a moisture-permeable resin film or the like. As the side leakage prevention sheet 6, a laminated nonwoven fabric having a high water pressure resistance, a laminate of a resin film and a nonwoven fabric, or the like can be used.

As shown in FIG. 1, the napkin 1 has a vertical direction X corresponding to the front-back direction of the wearer and a horizontal direction Y orthogonal to the vertical direction X. In addition, the napkin 1 has an excretion part opposing part B having an excretion spot part P disposed opposite to a wearer's liquid excretion part such as a vaginal opening in the longitudinal direction X and the lateral direction Y center part, and the excretion part opposing part. A front portion A disposed closer to the abdomen (front side) of the wearer than B; and a rear portion C disposed closer to the back side (rear side) of the wearer than the excretion portion facing portion B. ing. That is, the napkin 1 is divided in the longitudinal direction X into a front part A, an excretion part facing part B, and a rear part C in this order.

In the absorbent article of the present invention, the skin-facing surface is a surface of the napkin 1 or a component thereof (for example, the topsheet 2 and the absorbent core 41) that faces the wearer's skin when the napkin 1 is worn. The skin-facing surface is a surface of the napkin 1 or a component thereof that faces the side opposite to the skin side (usually the clothes side) when the napkin 1 is worn. The excretion spot portion P is a portion that is disposed to face the liquid excretion portion of the wearer and is directly supplied with menstrual blood when the absorbent article such as the napkin 1 is worn. B is located at the center in the vertical direction X and the horizontal direction Y.

  In the absorbent article of the present invention, when the excretion part facing part B has a so-called wing part as in the napkin 1 of the present embodiment, in the longitudinal direction X of the absorbent article, the vertical direction of one wing part It means a region sandwiched between the base along the direction X and the base along the longitudinal direction X of the other wing. In addition, when the absorbent article does not have a wing portion, two fold curves that are generated when the absorbent article is folded into a three-fold individual packaging form and traverse the absorbent article in the horizontal direction Y (Not shown) means an area surrounded by the first fold curve and the second fold curve, counted from the front end in the longitudinal direction X of the absorbent article.

  In the napkin 1, the topsheet 2 covers the entire surface of the absorbent body 4 facing the skin, and the backsheet 3 covers the entire area of the non-skin facing surface of the absorbent body 4. In the top sheet 2 and the back sheet 3, portions extending from both end edges in the longitudinal direction X of the absorber 4 are joined to each other. In the back sheet 3 and the side leakage prevention sheet 6, portions extending outward in the horizontal direction Y from both side edges along the vertical direction X of the absorber 4 are joined to each other. Thus, the absorber 4 is sandwiched between the top sheet 2 and the back sheet 3. Any bonding means such as an adhesive, a heat seal, an ultrasonic seal, or the like is used for bonding between the sheets constituting the napkin 1.

  The absorbent article of the present invention has side leakage prevention grooves on both sides of the longitudinal center line on the skin-facing surface. As shown in FIG. 1, the napkin 1 of the embodiment has side leakage prevention grooves 81, 81 extending in the vertical direction X on both sides of the vertical center line CL on the skin-facing surface of the napkin 1. Each of the side leakage prevention grooves 81 is configured such that a plurality of short grooves 81a to 81c in which the topsheet 2 is recessed in the absorber 4 are arranged in the vertical direction Y so as to have a gap 81d between the short grooves. have. At the end on the front part A side of each of the side leakage prevention grooves 81, a front leakage prevention groove 82 having a plan view shape curved or bent convexly forward is disposed close to the front leakage prevention groove 81. At the end on the side of the rear part C, a rear leakage-preventing groove 83 having a plan view shape that is curved or bent to project rearward is arranged in proximity. The pair of side leakage prevention grooves 81, 81, the front leakage prevention groove 82, and the rear leakage prevention groove 83 form an annular leakage prevention groove 8 composed of a plurality of intermittently disposed leakage prevention grooves. The annular leakage prevention groove 8 is formed so as to surround the excretion spot P.

  Each of the pair of side leakage prevention grooves 81 extends in the vertical direction X of the napkin 1 on both sides of the excretion spot portion P in the horizontal direction Y. It is preferable that the pair of side leakage prevention grooves 81, 81 extend in the vertical direction X at least on both sides of the excretion portion facing portion B with the excretion spot portion P interposed therebetween. The side leakage prevention grooves 81 preferably extend from the excretory portion facing portion B to the front portion A or the rear portion C, respectively, and as shown in FIG. 1, the front portion A, the excretory portion facing portion B More preferably, it extends over the rear portion C.

The side leakage prevention grooves 81 in the present embodiment are located as a plurality of short grooves 81a to 81c in the excretion portion opposing portion B, preferably at portions located on both sides of the excretion spot portion P in the lateral direction Y. A short central groove 81b, a front short groove 81a located forward of the central short groove 81b, and a rear short groove 81c located rearward of the central short groove 81b.
As shown in FIGS. 3A and 3B, the short grooves adjacent in the vertical direction X, that is, the front short groove 81a and the central short groove 81b, and the central short groove 81b and the rear short groove 81c are formed with a gap 81d. Are arranged close to each other. In the gap 81d between the short grooves adjacent in the vertical direction X, the distance W (see FIG. 3B) between the two points P1 and P2 at which the distance between the short grooves is minimized is the flexibility of the absorbent article. From the viewpoint of improvement, it is preferably at least 0.5 mm, more preferably at least 1 mm, and from the viewpoint of improvement of leakproofing, is preferably at most 10 mm, more preferably at most 8 mm, and is flexible. It is preferably 0.5 mm or more and 10 mm or less, and more preferably 1 mm or more and 8 mm or less, from the viewpoint of the balance between the resistance and the leakproofness.

  In each of the short grooves 81a to 81c, the front leak-proof groove 82, and the rear leak-proof groove 83 constituting the side leak-proof groove 81, the skin-facing surface side of the absorber 4 is depressed into a groove shape together with the topsheet 2. In the absorber 4, portions where the grooves 81a to 81c, 82, and 83 are formed are portions of the absorber 4 located on both sides of the grooves 81a to 81c, 82, and 83, respectively. And more compact. The short grooves 81 a to 81 c, the front leak-proof groove 82, and the rear leak-proof groove 83 constituting the side leak-proof groove 81 are, for example, pressurized or stacked on the top sheet 2 and the absorber 4. It can be formed by embossing involving heating and pressing. The main role of each of the leakage preventing grooves 81 to 83 is to suppress liquid diffusion in the plane direction of the napkin 1.

As shown in FIG. 2, the absorbent body 4 of the napkin 1 has an absorbent core 41 containing pulp fibers and a core wrap sheet 42 covering the absorbent core 41.
The core wrap sheet 42 in the present embodiment is wound down on the skin-side portion 42 a that covers the skin-facing surface side of the absorbent core 41 and the non-skin-facing surface side of the absorbent core 41. And a non-skin portion 42b covering the non-skin facing surface side. The core wrap sheet 42 has an overlapping portion 42c between the sheets in the non-skin portion 42b.
The core wrap sheet covering the absorbent core 41 may cover the entirety of the absorbent core 41 with one sheet, or may cover the entirety of the absorbent core 41 with two or more sheets. For example, the skin facing surface side and the non-skin facing surface side of the absorbent core 41 may be covered with separate sheets. Regardless of the number of sheets used for covering the absorbent core 41, the core wrap sheet covering the skin-facing surface side of the absorbent core 41 is replaced with the skin-side core wrap sheet 42a and the non-absorbent core 41. The portion covering the skin facing surface side is also referred to as a non-skin side core wrap sheet 42b.

  In the napkin 1 of the first embodiment, the circular portion indicated by reference numeral 9 of the skin-side portion (skin-side core wrap sheet) 42a that covers the skin-facing surface side of the absorbent core 41 in the core wrap sheet 42 is a hemagglutinating agent. And a coagulant disposing portion 9 including The skin-side core wrap sheet 42 a is one of the lower members disposed closer to the back sheet 3 than the top sheet 2 in the thickness direction of the napkin 1. The napkin 1 has a skin-side core wrap sheet 42a, an absorbent core 41, and a non-skin-side core wrap sheet 42b as lower members. It is preferable that the coagulant disposing portion 9 containing the hemagglutinating agent is formed at least on the skin-side core wrap sheet 42a which is a lower member adjacent to the topsheet 2 in the thickness direction of the absorbent article. The coagulant disposing portion 9 containing the hemagglutinating agent may be formed only on the skin-side core wrap sheet 42a, but is preferably formed on the skin-side core wrap sheet 42a and the absorbent core 41, and furthermore, More preferably, it is formed so as to cover the side core wrap sheet 42a, the absorbent core 41, and the non-skin side core wrap sheet 42b. The coagulant dispensing section 9 containing the hemagglutinating agent is adjacent to the non-skin-facing surface of the topsheet 2 irrespective of the structure of the absorber 4 and whether or not there is a second sheet between the topsheet 2 and the absorber 4. It is preferable to cover all the lower members from the member to be formed to the member adjacent to the skin facing surface of the back sheet 3. In any of these embodiments, the agglutinating agent disposing portion 9 is a “site in the lower member where the hemagglutinating agent is disposed”.

FIGS. 3A and 3B show the napkin 1 according to the first embodiment with the short grooves 81a to 81c, the front leak-proof groove 82, and the rear leak-proof groove 83 constituting the side leak-proof groove 81; FIG. 4 is a schematic plan view showing a positional relationship with a flocculant disposing portion 9. As shown in FIG. 3A, in the napkin 1 of the first embodiment, the gap 81 d between the short grooves in each of the side leakage prevention grooves 81 and the vicinity of the inner side in the lateral direction of the gap 81 d correspond to the skin-side core wrap. It overlaps with the coagulant disposing portion 9 formed on the lower member such as the sheet 42a.
The expression “the gap or the vicinity of the inside in the horizontal direction of the gap overlaps with the coagulant disposing portion 9” includes the case where only the gap 81d overlaps the coagulant disposing portion 9 and the case where the gap 81d The case where only the vicinity near the inner side in the horizontal direction Y overlaps the coagulant disposing portion 9, and the case where the gap 81d and both the portions near the inner side in the horizontal direction Y of the gap 81d overlap the coagulant disposing portion 9. included. FIG. 3B shows a portion of the short groove forming the side leakage prevention groove 81 which overlaps with the flocculant disposing portion 9 indicated by the symbol S among the plural flocculant disposing portions 9 shown in FIG. Is shown.

As shown in FIG. 3B, the vicinity of the inside of the gap 81d in the lateral direction Y includes the vicinity N of the inflow side end c of the gap 81d into which menstrual blood supplied to the excretion spot portion P flows. Is preferable from the viewpoint of improving leakproofness.
In the vicinity of the inner side overlapping with the coagulant disposing portion 9, the shortest horizontal distance from the inflow side end c of the gap 81d to the coagulant disposing portion 9 is preferably 0 mm or more and 5 mm or less, more preferably 0 mm or more and 3 mm or less. It is as follows. In the napkin 1 of the first embodiment, since the coagulant disposing portion 9 is continuous so as to overlap both the gap 81d and the vicinity near the inside of the gap 81d, the coagulant from the inflow side end c of the gap 81d. The shortest distance in the horizontal direction to the arrangement portion 9 is 0 mm. FIG. 3C shows another example in which the vicinity of the inside of the gap 81d in the lateral direction Y includes the vicinity N of the end c on the inflow side of the gap 81d. In FIG. 3C, the left side is a vertical center line side close to the excretion spot P, and the right side is a side far from the excretion spot P. In the gap 81d between the adjacent short grooves 81a and 81b in the vertical direction X, the distance W between the two points P1 and P2 where the distance between the short grooves is minimum (see FIG. 3C) is the flexibility of the absorbent article. From the viewpoint of the improvement of the resistance, it is preferably at least 0.5 mm, more preferably at least 1 mm, and from the viewpoint of the improvement of leakproofing, preferably at most 10 mm, more preferably at most 8 mm, and flexible. It is preferably 0.5 mm or more and 10 mm or less, and more preferably 1 mm or more and 8 mm or less from the viewpoint of compatibility between the watertightness and the leakproofness.

  In the napkin 1 of the first embodiment, the side leakage prevention grooves 81 are provided between the front short groove 81a and the front leakage prevention groove 82 and between the rear short groove 81c and the rear leakage prevention groove 83, respectively. A gap 81e similar to the gap 81d between the short grooves to be formed is formed, and a coagulant formed in a lower member such as the skin side core wrap sheet 42a also in the gap 81e and in the vicinity of the inside of the gap 81e in the width direction. It overlaps with the arrangement part 9. When one or both of the gap 81e and the vicinity of the inside of the gap 81e in the width direction overlap with the coagulant disposing portion 9, the movement of menstrual blood through the gap 81e is suppressed, and the performance of preventing the napkin 1 from leaking is improved. It is preferred.

FIG. 4 is a plan view showing a sanitary napkin 1A (hereinafter, also referred to as “napkin 1A”) according to a second embodiment of the present invention. 9A is also shown. In the napkin 1A of the second embodiment, a pair of band-shaped coagulant disposing portions 9A and 9A are respectively provided on both sides of the longitudinal center line CL of the absorbent article in the lower member such as the skin-side core wrap sheet 42a. It is formed to extend in the vertical direction X. More specifically, the coagulant disposing portions 9A, 9A are formed to extend continuously in the vertical direction X on both sides of the excretion spot portion P in a plan view of the napkin 1, respectively. It is preferable because the movement of menstrual blood from the inside to the outside of the groove is suppressed, and good leak-proof performance is maintained.
Also in the napkin 1A of the second embodiment, each of the pair of side leakage prevention grooves 81 has a front short groove 81a, a central short groove 81b, and a rear short groove 81c. The gap 81d between the short grooves adjacent to each other in the vertical direction X and the vicinity of the inside of the gap 81d in the horizontal direction overlap with the coagulant disposing portion 9A.
In addition, the point which does not specifically describe about the napkin 1A of 2nd Embodiment is the same as that of the napkin 1 of 1st Embodiment, and description about 1st Embodiment is applied suitably.

The core wrap sheet is used for the purpose of enhancing the shape retention of an absorbent core having insufficient shape retention by itself or preventing leakage of the constituent material of the absorbent core. Fiber sheet is used.
Examples of the cellulosic fiber constituting the thin paper include wood pulp fiber, rayon fiber, cotton fiber, and cellulose acetate fiber. Examples of the raw material pulp for cellulosic fibers include non-wood pulp such as wood pulp such as softwood kraft pulp or hardwood kraft pulp, cotton pulp, and straw pulp. These cellulosic fibers can be used alone or in combination of two or more. Also, from the viewpoint of improving strength, a small amount of non-cellulosic fibers can be mixed. Examples of the non-cellulosic fibers include polyolefin fibers such as polyethylene and polypropylene, and condensed fibers such as polyester and polyamide. The proportion of the cellulosic fiber in the constituent fibers of the thin paper is preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less, and further preferably 100% by mass or less.
A nonwoven fabric can also be used as the core wrap sheet. As the nonwoven fabric used for the core wrap sheet, nonwoven fabrics produced by various production methods can be used without particular limitation. For example, spunbonded nonwoven fabrics, melt blown nonwoven fabrics, and nonwoven fabrics obtained by entanglement of constituent fibers of a fiber web by high-speed water flow treatment are used. Spunlace nonwoven fabrics, air-through nonwoven fabrics which are nonwoven fabrics obtained by thermally fusing constituent fibers of a fiber web by hot air treatment, resin-bonded nonwoven fabrics which are nonwoven fabrics obtained by bonding constituent fibers of fiber webs with an adhesive, and the like. No. Fiber webs of spunlace nonwoven fabric, air-through nonwoven fabric, and resin-bonded nonwoven fabric can be manufactured by a carding machine or an air laid method in which fibers are stacked in air.

  Raw material fibers of the nonwoven fabric are made of synthetic resins such as wood pulp fibers, rayon fibers, cotton fibers, cellulose-based hydrophilic fibers such as cellulose acetate, polyolefins such as polyethylene and polypropylene, polyesters such as polyethylene terephthalate, and polyamides such as nylon. Synthetic fibers. As the synthetic fiber, a core-sheath type or a side-by-side type composite fiber can be used. Among these, for any of the above-mentioned nonwoven fabric manufacturing methods, the raw material fibers are preferably cellulosic fibers for the same reason as using thin paper. In the constituent fibers of the nonwoven fabric, the proportion of the cellulosic fiber is preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less, and further preferably 100% by mass or less. As the raw material fibers of the nonwoven fabric, one type can be used alone, or two or more types can be used in combination.

  The absorbent core 41 of the napkin 1 of the present embodiment is made of a mixed fiber of pulp fibers and a highly absorbent polymer. The mixed fiber stack is manufactured by a known drum type fiber stacking apparatus having a stacking drum having a stacking concave portion on the peripheral surface. On the surface, pulp fibers and a superabsorbent polymer as a material for forming the absorbent core are supplied in a scattered state, and the material for forming the absorbent core is deposited in the concave portion for accumulation, and then released from the concave portion for accumulation. It can be obtained by The absorbent core 41 of the napkin 1 of the present embodiment may be a single pile of pulp fibers containing no superabsorbent polymer.

  Examples of the pulp fibers constituting the absorbent core 41 include wood-based pulp fibers, rayon fibers, cotton fibers, and cellulose-based hydrophilic fibers such as cellulose acetate. These fibers can be used alone or in combination of two or more. Examples of the raw material pulp for pulp fibers include non-wood pulp such as wood pulp such as softwood kraft pulp or hardwood kraft pulp, cotton pulp, and straw pulp. Further, from the viewpoint of improving the strength, the absorbent core 41 may include, in addition to pulp fibers made of cellulose-based hydrophilic fibers, synthetic fibers such as polyolefin-based fibers such as polyethylene and polypropylene, and condensation-based fibers such as polyester and polyamide. You may mix a small amount. In the present invention, the absorbent core has a pulp fiber (cellulose-based fiber), in particular, a proportion of wood pulp fiber of preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less. Preferably it is 100% by mass.

  Further, the absorbent core 41 may contain a water-absorbing polymer. As the superabsorbent polymer, a particulate polymer is generally used, but a fibrous polymer may be used. When a particulate superabsorbent polymer is used, its shape may be spherical, massive, bales, or amorphous. Generally, a polymer or copolymer of acrylic acid or an alkali metal acrylate can be used as the superabsorbent polymer. Examples include polyacrylic acid and its salts and polymethacrylic acid and its salts. As the polyacrylate or polymethacrylate, a sodium salt can be preferably used. In addition, maleic acid, itaconic acid, acrylamide, 2-acrylamido-2-methylpropanesulfonic acid, 2- (meth) acryloylethanesulfonic acid, 2-hydroxyethyl (meth) acrylate, styrenesulfonic acid, etc. may be used for acrylic acid or methacrylic acid. A copolymer obtained by copolymerizing the above comonomer within a range that does not deteriorate the performance of the superabsorbent polymer can also be used. By containing the water-absorbing polymer, a large amount of excrement such as blood can be rapidly absorbed and held more stably. Further, the absorbent core 41 may be blended with a deodorant, an antibacterial agent, and the like as needed.

  The method of forming a coagulant disposing portion by including a hemagglutinating agent in a napkin component such as the core wrap sheet 42 is not particularly limited as long as the component can hold the hemagglutinating agent. Dissolving the agent in an appropriate solvent such as water or ethanol, attaching the solution as desired to a desired portion of the component, and then drying to remove the solvent. It is preferable from the viewpoint of adhering it. As a method for causing the solution to adhere to the constituent member, a method of dropping the solution onto a predetermined portion of the constituent member and various coating methods can be adopted. For example, a spray method, a dipping method, a transfer method, a die coating, a gravure coating, an inkjet method, a liquid coating to a predetermined portion of a component using a known liquid coating apparatus such as a screen printing, and the like can be mentioned. . The drying may be any of drying by heating, drying by reduced pressure, and drying combining heating and reduced pressure, but may be natural drying instead of forced drying.

The napkins 1 and 1A of the first and second embodiments are used by being fixed to the crotch portion of shorts with an adhesive portion provided on the non-skin-facing surface of the napkin 1, like a normal sanitary napkin.
In the napkin 1 of the first embodiment and the napkin 1A of the second embodiment, the side leakage prevention groove 81 is not composed of one continuous leakage prevention groove, but is composed of a plurality of shorter grooves 81a to 81c having a shorter length. The napkins 1 and 1A are excellent in flexibility since the side leakage prevention grooves 8 can be bent in the gaps 81d between the short grooves adjacent to each other in the longitudinal direction X.
Moreover, even when menstrual blood is excreted in the excretion spot part P during wearing, the menstrual blood diffuses in the horizontal direction and reaches the gap 81d between the short grooves in the side leakage prevention groove 8. A hemagglutinating agent disposed in the vicinity of the gap 81d or the gap 81d located in front of the gap 81d in the lateral direction acts on the menstrual blood to generate an agglutinate 16 of red blood cells in the menstrual blood. The diffusion of the blood 11 from the inside to the outside of the side leakage prevention groove 81 through the gap 81d between the short grooves is suppressed. Thereby, occurrence of leakage such as lateral leakage is prevented.
Further, even if the menstrual blood component diffuses in the vertical direction, wraps around the front leak-proof groove 82 and the rear leak-proof groove 83, and reaches the gap 81e between the short grooves, the horizontal direction of the gap 81e is The blood cell aggregating agent disposed in the vicinity of the inside acts on the menstrual blood to generate red blood cell agglomerates 16, so that the menstrual blood 11 passes through the short gap 81 e from the inside of the side leakage prevention groove 81. Leakage prevention performance is maintained by suppressing diffusion to the outside.

By such an action, the napkins 1 and 1A of the first and second embodiments are excellent in both flexibility and leakproof performance. Further, even if a gap is formed between the topsheet 2 and the absorber 4 in the leakage preventing groove 8 formed by integrally pressing and compressing the topsheet 2 and the absorber 4, the same applies. Then, the blood cell aggregating agent contained in the lower member such as the skin-side core wrap sheet 42 acts on the menstrual blood that has entered the gap between the topsheet 2 and the absorber 4 to absorb the blood in and around the gap. From the viewpoint of preventing menstrual blood from leaking outward across the side leakage prevention grooves 81 by forming the red blood cell aggregates 16 in the body 4, a lower member such as the skin-side core wrap sheet 42a is used. The coagulant disposing portion 9 or 9A preferably satisfies one or more of the following conditions (1) to (3).
(1) The agglutinating agent disposing part 9 or 9A has an abundance per unit area of the hemagglutinating agent per unit area of 6 g / m ² or more in an overlapping portion overlapping the side leakage preventing groove 81 extending in the longitudinal direction X of the leakage preventing groove 8. It is 80 g / m ² or less, more preferably 12 g / m ² or more and 70 g / m ² or less.
Here, the amount of the hemagglutinating agent, when the hemagglutinating agent is a cationic polymer, is the pure amount of the cationic polymer, the amount per unit area of the hemagglutinating agent is measured as follows Is done.
[Method of measuring the amount of hemagglutinating agent per unit area]
After the solution in which the cationic polymer is dissolved is applied to the lower member, the lower member is allowed to stand at 30 ° C. and 10% RH for 2 hours and dried. Next, the coagulant disposition portion is cut out from the lower member, the area and the weight thereof are measured, and the weight of the lower member having the same size as the cut coagulant disposition portion is subtracted from the measured weight to remove the cation in the coagulant disposition portion. The amount of the hemagglutinating agent per unit area is calculated by calculating the weight of the aggregating polymer and dividing the weight by the area of the aggregating agent disposing portion.

(2) From the viewpoint of effectively improving the ability to form the red blood cell agglomerate 16 and the leakage preventing effect thereof while suppressing the total amount of the hemagglutinating agent to be used, the side extending in the longitudinal direction X of the leakage preventing groove 8. It is preferable that the abundance per unit area of the hemagglutinating agent in the overlapping portion overlapping with the leak preventing groove 81 is larger than the abundance per unit area of the hemagglutinating agent not overlapping with the side leak preventing groove 81. Further, the absorbent article may have a portion where the hemagglutinating agent is not disposed at the center in the lateral direction. The hemagglutinating agent is not disposed at the central portion in the lateral direction, for example, the excretion spot portion P, and the hemagglutinating agent is disposed at a portion overlapping with the gap 81d between the short grooves constituting the side leakage prevention groove 81. However, by preventing the formation of aggregates in the vicinity of the excretion spot P, the leakage prevention effect can be improved without lowering the absorption amount, and it is more preferable that the skin can be prevented from causing discomfort. .

(3) The cationic polymer used as a hemagglutinating agent has a molecular weight of preferably 2,000 or more, more preferably 10,000 or more, and still more preferably 150,000 or more. The upper limit of the molecular weight is preferably 30,000,000 or less, more preferably 22,000,000 or less, and even more preferably 10,000,000 or less. Further, it is preferably from 2,000 to 30,000,000, more preferably from 10,000 to 22,000,000, and still more preferably from 150,000 to 10,000,000.

  Further, it is preferable that the entire surface sheet 2 of the napkin 1, 1A is hydrophilic, and at least a portion overlapping with the coagulant disposing portions 9, 9A and the leakage preventing groove 8, particularly the side leakage preventing groove 81 is provided. It is preferably hydrophilic. When the topsheet 2 is hydrophilic, when the menstrual blood that is hydrophilic diffuses in the absorber, it also efficiently diffuses in the side leakage prevention grooves 81 that partially or entirely overlap the coagulant disposing portion 9. You can do it.

  As a method for making the whole or a part of the topsheet 2 hydrophilic, the topsheet 2 may be made of a non-woven fabric mainly composed of cellulosic fibers such as wood pulp fiber, rayon fiber, cotton fiber, cellulose acetate fiber, or polyethylene. And a method of using a nonwoven fabric or the like whose main constituent fibers are fibers obtained by hydrophilizing synthetic fibers such as polyolefin fibers such as polypropylene and condensation fibers such as polyester and polyamide with a hydrophilic oil agent.

The short groove in the absorbent article of the present invention may be linear in plan view, but is preferably non-linear as in the napkins 1 and 1A of the first and second embodiments. In the short grooves 81a to 81c of the napkins 1 and 1A of the first and second embodiments, as shown in FIG. 3A, the front short groove 81a and the rear short groove 81c face inward in the lateral direction Y. And has one curved portion b curved outwardly in the lateral direction Y. The central short groove 81b has a curved portion a curved outwardly in the lateral direction Y. It is preferable to have one curved portion b curved toward the convex shape and two curved portions a located before and after the curved portion b curved inwardly in the lateral direction Y. Having one curved portion convexly curved outwardly causes the napkin to protrude toward the wearer's skin side when an external force is applied from the left and right in the lateral direction Y toward the center of the wing portion of the napkin. Therefore, the external force is dispersed, and the external force applied to the side leakage prevention groove 81 is reduced. As a result, peeling of the topsheet from the absorber in the side leakage prevention groove 81 and the degree and frequency of the gap generated in the pressurized and compressed portion of the absorber are reduced. Therefore, it is preferable from the viewpoint of preventing the liquid from moving by the leak preventing groove and further improving the leak preventing performance of the absorbent article.
Further, since the short grooves 81a to 81c constituting the side leakage prevention grooves 81 are non-linear, the side leakage prevention grooves 81 are more easily bent, and the short grooves 81a to 81c are formed in the lateral direction. When at least one curved portion a or b that is convexly curved outward or outward is provided, the side leakage prevention groove 81 is more easily bent.
If a hemagglutinating agent is contained in a lower member such as the skin-side core wrap sheet 42a, the flexibility of the lower member may be reduced depending on the type and amount of application. When the side leakage prevention groove 81 is non-linear, more preferably non-linear having one or more curved portions a and b, the napkins 1 and 1A are more easily bent, and the lower member made of a hemagglutinating agent is used. The effect of improving flexibility, which is sufficiently larger than the effect of the hardening, can be obtained.

  As the hemagglutinating agent used in the hemagglutinating fiber of the present invention, a hemagglutinating agent having an action capable of aggregating red blood cells in blood is used. Red blood cells aggregated by the hemagglutinating agent form aggregates. Cationic polymers are useful as hemagglutinating agents. The reason is as follows. Red blood cells have a red blood cell membrane on their surface. The erythrocyte membrane has a two-layer structure. This two-layer structure is composed of a red blood cell membrane skeleton as a lower layer and a lipid film as an upper layer. The lipid membrane exposed on the surface of erythrocytes contains a protein called glycophorin. Glycophorin has at its terminal a sugar chain to which a sugar having an anionic charge called sialic acid is bonded. As a result, erythrocytes can be treated as anionic charged colloid particles. An aggregating agent is generally used for agglomeration of colloid particles. Considering that erythrocytes are anionic colloid particles, it is advantageous to use a cationic substance as the aggregating agent from the viewpoint of neutralizing the electric double layer of erythrocytes. When the aggregating agent has a polymer chain, the entanglement of the polymer chains of the aggregating agent adsorbed on the surface of the erythrocyte is apt to occur, which promotes the agglutination of the erythrocyte. Further, it is preferable that the aggregating agent has a functional group, since the aggregation of erythrocytes is promoted by the interaction between the functional groups. According to the hemagglutinating agent (cationic polymer), it becomes possible to form an agglutinate of red blood cells in menstrual blood by the above mechanism of action.

Blood cell aggregating agent in the present invention are those having an effect capable of aggregating red blood cells in the blood, specifically, the pseudo blood below, the measurement sample agent when added 1000 ppm, the fluidity of the blood In this state, at least two or more red blood cells are aggregated to form an aggregate. With such properties, formed red blood cells by aggregating aggregates in blood, and the aggregates and plasma component of red blood cells which form the form is separated.

  The above-mentioned "state in which the fluidity of blood is maintained" means that 10 g of the simulated blood to which 1000 ppm of the measurement sample agent was added was added to a screw tube bottle (manufactured by Maruem Co., Ltd., product number "screw tube No. 4," 14.5 mm in inner diameter, (Diameter: 27 mm, total length: 55 mm) means that, when the screw vial containing the simulated blood is turned 180 degrees, 80% or more of the simulated blood flows down within 5 seconds. The simulated blood is such that the viscosity measured using a B-type viscometer (manufactured by Toki Sangyo Co., Ltd., model number TVB-10M, rotor No. 19, 30 rpm, 25 ° C., 60 seconds) is 8 mPa · s. The blood cell / plasma ratio of defibrillated horse blood (manufactured by Japan Biotest Laboratory Co., Ltd.) was prepared.

  Whether or not the above-mentioned "two or more red blood cells are aggregated to form an aggregate" is determined as follows. That is, simulated blood to which 1000 ppm of a measurement sample agent was added was diluted 4000 times with physiological saline, and a laser diffraction / scattering type particle size distribution analyzer (manufactured by HORIBA, model number: LA-950V2, measurement conditions: flow cell measurement) When the average median diameter of the volume particle diameter measured at a temperature of 25 ° C. by a laser diffraction scattering method using a circulation speed of 1, and no ultrasonic waves is 10 μm or more, “2 or more red blood cells are aggregated. To form aggregates. "

  The hemagglutinating agent used in the present invention satisfies the above properties by a single compound that satisfies the above properties, a plurality of combinations of a single compound that satisfies the above properties, or a combination of a plurality of compounds (agglutination of red blood cells). ) Agent. That is, the hemagglutinating agent is an agent limited to those having the hemagglutinating action as defined above. Therefore, when a hemagglutinating agent includes a third component that does not meet the above definition, it is expressed as a hemagglutinating agent composition and is distinguished from a hemagglutinating agent.

  Suitable examples of the hemagglutinating agent used in the present invention include those containing a cationic polymer. Examples of the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride starch. In addition, the hemagglutinating agent used in the present invention may contain a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate as a cationic polymer. In the present invention, the “quaternary ammonium salt” includes a compound having a positive monovalent charge at the position of a nitrogen atom or a compound generating a positive monovalent charge at the position of a nitrogen atom by neutralization. Specific examples thereof include salts of quaternary ammonium cations, neutralized salts of tertiary amines, and tertiary amines that take on cations in an aqueous solution. The “quaternary ammonium site” described below is also used in the same meaning, and is a site that is positively charged in water. In the present invention, the term “copolymer” refers to a polymer obtained by copolymerization of two or more polymerizable monomers, and includes a binary copolymer and a terpolymer or higher copolymer. Include both things. In the present invention, the “polycondensate” is a polycondensate obtained by polymerizing a condensate composed of two or more monomers.

  When the hemagglutinating agent used in the present invention contains a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate as the cationic polymer, The agent may include any one of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer and a quaternary ammonium salt polycondensate, or a combination of any two or more types. May be included. In addition, the quaternary ammonium salt homopolymer can be used alone or in combination of two or more. Similarly, the quaternary ammonium salt copolymer can be used alone or in combination of two or more. Further, similarly, the quaternary ammonium salt polycondensate can be used alone or in combination of two or more. As described above, the term “hemagglutinating agent” as used herein refers to a single compound capable of agglutinating red blood cells of blood, or a combination of the single compounds, or agglutination of red blood cells by a combination of a plurality of compounds. Is an agent that expresses That is, the hemagglutinating agent is an agent limited to an agent having a hemagglutinating action. Therefore, when the hemagglutinating agent contains the third component, it is referred to as a hemagglutinating agent composition and is distinguished from the hemagglutinating agent. Here, the “single compound” is a concept that includes compounds having the same composition formula but different molecular weights due to different numbers of repeating units.

  Among the various cationic polymers described above, the use of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate is particularly preferable from the viewpoint of adsorption to erythrocytes. preferable. In the following description, for convenience, the quaternary ammonium salt homopolymer, the quaternary ammonium salt copolymer and the quaternary ammonium salt polycondensate are collectively referred to as “quaternary ammonium salt polymer”.

  The quaternary ammonium salt homopolymer is obtained by polymerizing one polymerizable monomer having a quaternary ammonium moiety. On the other hand, the quaternary ammonium salt copolymer uses at least one polymerizable monomer having a quaternary ammonium moiety, and optionally includes at least one polymerizable monomer having no quaternary ammonium moiety. It is obtained by copolymerizing these with seeds. That is, the quaternary ammonium salt copolymer is obtained by copolymerizing two or more polymerizable monomers having a quaternary ammonium moiety, or is obtained by copolymerizing these. It is obtained by using one or more polymerizable monomers having one or more polymerizable monomers having no quaternary ammonium moiety and copolymerizing these. The quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer. The quaternary ammonium salt polycondensate is obtained by using a condensate composed of at least one monomer having a quaternary ammonium moiety and polymerizing the condensate. That is, the quaternary ammonium salt polycondensate is obtained by polymerizing a condensate of two or more kinds of monomers having a quaternary ammonium moiety, or is obtained by polymerizing the quaternary ammonium moiety. Is obtained by condensation polymerization of a condensate comprising at least one monomer having the formula (I) and at least one monomer having no quaternary ammonium moiety.

  A quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium moiety. The quaternary ammonium moiety can be generated by quaternary ammoniumation of a tertiary amine using an alkylating agent. Alternatively, a tertiary amine can be dissolved in an acid or water and generated by neutralization. Alternatively, it can be produced by quaternary ammonium conversion by a nucleophilic reaction including a condensation reaction. Examples of the alkylating agent include alkyl halides and dialkyl sulfates such as dimethyl sulfate and dimethyl sulfate. Of these alkylating agents, the use of dialkyl sulfate is preferred because corrosion problems that may occur when an alkyl halide is used do not occur. Examples of the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, hyaluronic acid and the like. . In particular, it is preferable to use a quaternary ammonium salt polymer in which a tertiary amine moiety is quaternary ammonium-modified with an alkylating agent since the electric double layer of red blood cells can be reliably neutralized. The quaternary ammonium conversion by a nucleophilic reaction including a condensation reaction can be caused as in a ring-opening polycondensation reaction between dimethylamine and epichlorohydrin and a cyclization reaction between dicyandiamide and diethylenetriamine.

  The present inventors have found that the use of a cationic polymer is particularly effective for producing aggregates of red blood cells during menstrual blood. The reason is as follows. Red blood cells have a red blood cell membrane on their surface. The erythrocyte membrane has a two-layer structure. This two-layer structure is composed of a red blood cell membrane skeleton as a lower layer and a lipid film as an upper layer. The lipid membrane exposed on the surface of erythrocytes contains a protein called glycophorin. Glycophorin has at its terminal a sugar chain to which a sugar having an anionic charge called sialic acid is bonded. As a result, erythrocytes can be treated as anionic charged colloid particles. An aggregating agent is generally used for agglomeration of colloid particles. Considering that erythrocytes are anionic colloid particles, it is advantageous to use a cationic substance as the aggregating agent from the viewpoint of neutralizing the electric double layer of erythrocytes. When the aggregating agent has a polymer chain, the entanglement of the polymer chains of the aggregating agent adsorbed on the surface of the erythrocyte is apt to occur, which promotes the agglutination of the erythrocyte. Further, it is preferable that the aggregating agent has a functional group, because the aggregation of the red blood cells is promoted by the interaction between the functional groups.

As described above, the cationic polymer used as a hemagglutinating agent has a molecular weight of preferably 2,000 or more, more preferably 10,000 or more, and more preferably 10,000 or more, from the viewpoint of effectively forming a red blood cell aggregate. More preferably, it is at least 10,000. When the molecular weight of the cationic polymer is higher than these values, the entanglement of the cationic polymer between erythrocytes and the cross-linking of the cationic polymer between erythrocytes are sufficiently generated, and menstrual blood has an effect on the aggregation of erythrocytes. It is more preferable because the effect of suppressing the diffusion of blood is enhanced by the effective formation of blood. The upper limit of the molecular weight is preferably 30,000,000 or less, more preferably 22,000,000 or less, and even more preferably 10,000,000 or less. When the molecular weight of the cationic polymer is equal to or less than these values, the cationic polymer dissolves well in menstrual blood. The molecular weight of the cationic polymer is such that menstrual blood is separated into red blood cells and plasma, effectively forming red blood cell agglomerates, and plasma is efficiently absorbed by the superabsorbent polymer, increasing the amount and speed of absorption and preventing leakage. From the viewpoint of suppressing the movement of menstrual blood from the inside to the outside of the groove and maintaining good leak-proof performance, it is preferably 2,000 to 30,000,000, more preferably 10,000 to 22,000,000. , More preferably 150,000 or more and 10,000,000 or less.
The molecular weight of the cationic polymer can be controlled by appropriately selecting the polymerization conditions. Further, two or more cationic polymers having different molecular weights may be combined within the above-mentioned molecular weight range. The molecular weight of the cationic polymer can be measured using HLC-8320GPC manufactured by Tosoh Corporation. Specific measurement conditions are as follows. In addition, the molecular weight referred to in the present invention is a weight average molecular weight.

  As the column, a column in which a guard column α manufactured by Tosoh Corporation and an analysis column α-M are connected in series is used at a column temperature of 40 ° C. The detector uses RI (refractive index). As a measurement sample, 1 mg of the treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 1 mL of the eluent. As the copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, an eluent obtained by dissolving 150 mmol / L sodium sulfate and 1% by mass acetic acid in water is used. The copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is prepared by using 10 mL of eluent as pullulan having a molecular weight of 5900, pullulan having a molecular weight of 47300, pullulan having a molecular weight of 212,000, and pulling a molecular weight of 788,000. Pullulan, 2.5 mg each of which is dissolved in a pullulan mixture is used as the molecular weight standard. The copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is measured at a flow rate of 1.0 mL / min and an injection volume of 100 μL. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, elution was performed by dissolving 50 mmol / L lithium bromide and 1% by mass acetic acid in ethanol: water = 3: 7 (volume ratio). Use liquid. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, polyethylene glycol (PEG) having a molecular weight of 106, PEG having a molecular weight of 400, PEG having a molecular weight of 1470, and PEG having a molecular weight of 6450 were used for 20 mL of the eluent. As a molecular weight standard, polyethylene oxide (PEO) having a molecular weight of 50,000, PEO having a molecular weight of 235,000, PEO having a molecular weight of 875,000, and a PEG-PEO mixture in which 10 mg of each is dissolved are used. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the flow rate is measured at 0.6 mL / min and the injection volume is measured at 100 μL.

  The cationic polymer is preferably water-soluble from the viewpoint of effectively forming an aggregate of red blood cells. In the present invention, “water-soluble” means that 0.05 g of a 1 mm or less powdered cationic polymer or a 0.5 mm or less film cationic polymer is added to 50 mL of ion exchange water at 25 ° C. in a 100 mL glass beaker (5 mmΦ). Then, a stirrer chip having a length of 20 mm and a width of 7 mm is put therein, and the whole amount thereof is dissolved in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by As One Corporation. In the present invention, as more preferable solubility, it is preferable that the whole amount is dissolved in water within 3 hours, and it is more preferable that the whole amount is dissolved in water within 30 minutes.

  The cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. In particular, the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. The quaternary ammonium moiety is preferably present on the side chain. In this case, when the main chain and the side chain are bonded at one point, the flexibility of the side chain is less likely to be impaired, and the quaternary ammonium site present in the side chain is smoothly placed on the surface of the erythrocyte. It will be adsorbed. However, in the present invention, it is not prevented that the main chain and the side chain of the cationic polymer are bonded at two or more points. In the present invention, “bonded at one point” means that one of the carbon atoms constituting the main chain is single-bonded to one carbon atom located at the end of the side chain. . "Bonded at two or more points" means that two or more of the carbon atoms constituting the main chain are each single-bonded to two or more carbon atoms located at the end of the side chain. Say.

When the cationic polymer has a structure having a main chain and a plurality of side chains bonded thereto, for example, a quaternary ammonium salt polymer having a structure having a main chain and a plurality of side chains bonded thereto In this case, the number of carbon atoms in each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more. The upper limit of the carbon number is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less. For example, the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and even more preferably 6 or more and 8 or less. The number of carbon atoms in the side chain refers to the number of carbon atoms in the quaternary ammonium moiety (cation moiety) in the side chain. Even if carbon is contained in the counter ion, the carbon is counted in the counting. Not included. In particular, among the carbon atoms in the side chain, the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is within the above-mentioned range. This is preferable because steric hindrance when the polymer is adsorbed on the surface of red blood cells is reduced.

  When the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer, examples of the homopolymer include a polymer of a vinyl monomer having a quaternary ammonium moiety or a tertiary amine moiety. . When a vinyl monomer having a tertiary amine moiety is polymerized, a quaternary ammonium salt homogenized by quaternizing the tertiary amine moiety with an alkylating agent before and / or after polymerization. It becomes a polymer, becomes a tertiary amine neutralized salt in which a tertiary amine moiety is neutralized with an acid before and / or after polymerization, or becomes a tertiary amine which becomes cationic in an aqueous solution after polymerization. . Examples of the alkylating agent and the acid are as described above.

  Particularly, the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1.

  Specific examples of the quaternary ammonium salt homopolymer include polyethyleneimine. Also, poly (2-methacryloxyethyldimethylamine quaternary salt) and poly (2-methacryloxyethyltrimethylammonium salt) in which a side chain having a quaternary ammonium moiety is bonded to the main chain at one point. ), Poly (2-methacryloxyethyldimethylethylammonium methyl sulfate), poly (2-acryloxyethyldimethylamine quaternary salt), poly (2-acryloxyethyltrimethylamine quaternary salt), poly (2-acryloxy Ethyldimethylethylammonium ethyl sulfate), poly (3-dimethylaminopropylacrylamide quaternary salt), polydimethylaminoethyl polymethacrylate, polyallylamine hydrochloride, cationized cellulose, polyethyleneimine, polydimethylaminopropylacrylamide, polyamidine, etc. And the like. On the other hand, examples of the homopolymer in which the side chain having a quaternary ammonium moiety is bonded to the main chain at two or more points include polydiallyldimethylammonium chloride and polydiallylamine hydrochloride.

When the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer, two kinds of polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above may be used as the copolymer. Copolymers obtained by copolymerization using the above can be used. Alternatively, as the quaternary ammonium salt copolymer, one or more polymerizable monomers used for the polymerization of the above-described quaternary ammonium salt homopolymer, and a polymerizable monomer having no quaternary ammonium moiety Copolymers obtained by copolymerizing one or more of the polymers can be used. Further, in addition to or instead of the vinyl polymerizable monomer, another polymerizable monomer, for example, —SO ₂ — or the like can be used. As described above, the quaternary ammonium salt copolymer may be a binary copolymer or a tertiary or higher copolymer.

  In particular, when the quaternary ammonium salt copolymer has the repeating unit represented by the above formula 1 and the repeating unit represented by the following formula 2, the erythrocyte aggregate is effectively formed. Preferred from a viewpoint.

  In addition, as the polymerizable monomer having no quaternary ammonium moiety, a cationic polymerizable monomer, an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used. By using a cationic polymerizable monomer or a nonionic polymerizable monomer among these polymerizable monomers, the charge can be offset with the quaternary ammonium moiety in the quaternary ammonium salt copolymer. Therefore, aggregation of red blood cells can be effectively caused. Examples of the cationic polymerizable monomer include a linear compound having a cation-bearing nitrogen atom in the main chain such as vinylpyridine as a cyclic compound having a cation-bearing nitrogen atom under a specific condition. Examples include a condensation compound of dicyandiamide and diethylenetriamine. Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropanesulfonic acid, methacrylic acid, acrylic acid, and styrenesulfonic acid, and salts of these compounds. On the other hand, examples of the nonionic polymerizable monomer include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol, propylene glycol, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate, methyl Examples include acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, and butyl acrylate. One of these cationic polymerizable monomers, anionic polymerizable monomers, or nonionic polymerizable monomers can be used, or two or more of them can be used in combination. Can be. Further, two or more cationic polymerizable monomers can be used in combination, two or more anionic polymerizable monomers can be used in combination, or two or more nonionic polymerizable monomers can be used in combination. Can also be used. Quaternary ammonium salt copolymers copolymerized using cationically polymerizable monomers, anionic polymerizable monomers and / or nonionic polymerizable monomers as polymerizable monomers have a molecular weight of However, as described above, it is preferably 10,000,000 or less, particularly preferably 5,000,000 or less, particularly preferably 3,000,000 or less (the same applies to quaternary ammonium salt copolymers exemplified below).

As the polymerizable monomer having no quaternary ammonium moiety, a polymerizable monomer having a functional group capable of forming a hydrogen bond can be used. When such a polymerizable monomer is used for copolymerization, when erythrocytes are agglutinated using a quaternary ammonium salt copolymer obtained therefrom, a hard agglomerated mass is easily generated, and a high-absorbent polymer is used. Absorption performance is more difficult to be hindered. The functional group capable of hydrogen bonding, for example _{-OH, -NH 2, -CHO, -COOH} , -HF, such as -SH and the like. Examples of the polymerizable monomer having a functional group capable of forming a hydrogen bond include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol, propylene glycol, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, Examples include hydroxyethyl methacrylate and hydroxyethyl acrylate. In particular, hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide, and the like, in which a hydrogen bond works strongly, are preferable because the state of adsorption of the quaternary ammonium salt polymer to erythrocytes is stabilized. These polymerizable monomers can be used alone or in combination of two or more.

  As the polymerizable monomer having no quaternary ammonium moiety, a polymerizable monomer having a functional group capable of performing hydrophobic interaction can be used. By using such a polymerizable monomer for copolymerization, the same advantageous effect as in the case of using a polymerizable monomer having a functional group capable of hydrogen bonding as described above, that is, hard red blood cells, An effect that an aggregate is easily generated is exerted. Examples of the functional group capable of performing hydrophobic interaction include an alkyl group such as a methyl group, an ethyl group, and a butyl group, a phenyl group, an alkylnaphthalene group, and a fluorinated alkyl group. Examples of the polymerizable monomer having a functional group capable of performing a hydrophobic interaction include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, and styrene. Is mentioned. In particular, methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, and the like, which strongly act on hydrophobic interaction and do not significantly reduce the solubility of the quaternary ammonium salt polymer, are adsorbed to erythrocytes by the quaternary ammonium salt polymer. Is preferred because it is stabilized. These polymerizable monomers can be used alone or in combination of two or more.

  The molar ratio of the polymerizable monomer having a quaternary ammonium moiety to the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer is determined by the quaternary ammonium salt. It is preferable that the erythrocytes are appropriately adjusted so as to be sufficiently aggregated by the ammonium salt copolymer. In particular, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably at least 10 mol%, more preferably at least 22 mol%, and more preferably 32 mol%. %, More preferably at least 38 mol%. Further, it is preferably at most 100 mol%, more preferably at most 80 mol%, even more preferably at most 65 mol%, even more preferably at most 56 mol%. Specifically, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety is preferably from 10 mol% to 100 mol%, more preferably from 22 mol% to 80 mol%, It is more preferably from 32 mol% to 65 mol%, more preferably from 38 mol% to 56 mol%.

  When the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate, as the polycondensate, use a condensate comprising at least one monomer having a quaternary ammonium moiety described above; Polycondensates obtained by polymerizing those condensates can be used. Specific examples include dicyandiamide / diethylenetriamine polycondensate, dimethylamine / epichlorohydrin polycondensate, and the like.

  The quaternary ammonium salt homopolymer and the quaternary ammonium salt copolymer described above can be obtained by a homopolymerization method or a copolymerization method of a vinyl polymerizable monomer. As the polymerization method, for example, radical polymerization, living radical polymerization, living cationic polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used. The polymerization conditions are not particularly limited, and conditions for obtaining a quaternary ammonium salt polymer having a desired molecular weight, streaming potential, and / or IOB value may be appropriately selected.

The cationic polymer described in detail above is an example of the above-mentioned " hemocyte agglutinating agent ", and the effect can be referred to in Examples 1 to 45 of Japanese Patent Application No. 2015-239286.

  In addition, the hemagglutinating agent used in the present invention may include, in addition to the polycation (cationic polymer), one other component such as a solvent, a plasticizer, a fragrance, an antibacterial / deodorant, and a skin care agent. It may be in the form of a composition (a hemagglutinating agent composition) containing the above. As the solvent, water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used. As the plasticizer, glycerin, polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol and the like can be used. As the fragrance, a fragrance having a green herbal-like fragrance, a plant extract, a citrus extract, or the like described in Japanese Patent No. 4776407 can be used. Antibacterial and deodorant agents include a cancrinite-like mineral containing an antibacterial metal described in Japanese Patent No. 4526271 and a polymerizable monomer having a phenyl group described in Japanese Patent No. 4587928. Porous polymers, quaternary ammonium salts, activated carbon, clay minerals and the like described in Japanese Patent No. 4651392 can be used. As the skin care agent, plant extracts, collagen, natural moisturizing components, moisturizers, keratin softeners, anti-inflammatory agents, and the like described in Japanese Patent No. 4084278 can be used.

  The proportion of the cationic polymer in the hemagglutinating agent composition is preferably 1% by mass or more, more preferably 3% by mass or more, even more preferably 5% by mass or more. Further, the content is preferably 50% by mass or less, more preferably 30% by mass or less, and still more preferably 10% by mass or less. By setting the proportion of the cationic polymer in the hemagglutinating agent composition within this range, an effective amount of the cationic polymer can be provided to the absorbent article.

Although the present invention has been described above, the present invention is not limited to the above-described embodiment, and can be appropriately changed without departing from the gist of the present invention. For example, in the napkins 1 and 1A of the first and second embodiments, the pair of side leakage prevention grooves 81 are configured by three short grooves 81a to 81c. The number of short grooves 81a to 81c to be formed is not limited to three. The number of the short grooves 81a to 81c constituting the side leakage prevention groove 81 is two or more, and preferably three or more. The upper limit is not particularly limited, but is preferably 5 or less, more preferably 4 or less. Further, the plurality of short grooves in the side leakage prevention grooves 81 may be arranged in a straight line in the vertical direction, or as a whole, the side grooves having a shape curved convexly inward in the horizontal direction Y. The leak-proof groove 81 may be formed, or the side leak-proof groove 81 may be formed in a shape that is convexly curved outward in the lateral direction Y. Further, from the viewpoint of improving the flexibility of the absorbent article and further improving the leakproofness, some or all of the short grooves 81a to 81c constituting the side leakproof groove 81 do not overlap in the horizontal direction Y. Alternatively, they may overlap in the vertical direction X.

  Further, the lower member containing the hemagglutinating agent may be a member other than the skin-side core wrap sheet, for example, an absorbent core or a non-skin side core wrap sheet. May be contained. For example, the hemagglutinating agent may be disposed so as to extend over any two or more of the skin side core wrap sheet, the absorbent core and the non-skin side core wrap sheet. A hemagglutinating agent may be disposed so as to cover the entirety of the sexual core and the non-skin side core wrap sheet.

In addition, the absorbent core 41 is not limited to the one in which the thickness is uniform over the entire area in the plane direction. For example, a part in the plane direction, for example, the central part of the excretion part facing part B, etc. It is also possible to form a raised portion that rises toward the skin side. Such a raised portion can be formed, for example, on a part of the absorbent core 41 by partially increasing the basis weight of a constituent material such as pulp fiber.
In addition, the absorbent article may not have the side leakage prevention sheet and the leakage prevention mechanism thereby, and may not have the wing part. In addition, the absorbent article of the present invention may be a panty liner (vegetable sheet) or the like in addition to a sanitary napkin.

With respect to the embodiment of the present invention described above, the present invention further discloses the following absorbent articles.
<1>
A liquid-permeable top sheet that forms the skin-facing surface, a back sheet that forms the non-skin-facing surface, and an absorber disposed between these two sheets, a longitudinal direction along the front-back direction of the wearer, and the longitudinal direction. An absorbent article for menstrual absorption having a transverse direction perpendicular to,
The skin-facing surface has side leakage-preventing grooves on both sides of a longitudinal center line, and the side leakage-preventing grooves are formed by a plurality of short grooves in which the topsheet is indented into the absorbent body. To have a gap, has a configuration arranged in the vertical direction,
The lower member disposed closer to the back sheet than the top sheet contains a hemagglutinating agent, and the gap in the side leakage prevention groove or the vicinity of the gap inside the gap in the lateral direction is the lower member. The absorbent article, which overlaps with the site where the hemagglutinating agent is disposed in the above.

<2>
The absorbent article according to <1>, wherein the absorbent article has a portion in which the hemagglutinating agent is not disposed at a lateral center of the absorbent article.
<3>
The absorbent article according to <1> or <2>, wherein the lower member is a member adjacent to the topsheet in a thickness direction of the absorbent article.
<4>
The portion in which the hemagglutinating agent is disposed in the lower member has an abundance per unit area of the hemagglutinating agent in a gap between the short grooves or in an overlapping portion overlapping the vicinity of the inside of the gap in the lateral direction, The absorbent article according to any one of <1> to <3>, which has a weight of 6 g / m ² or more and 80 g / m ² or less.
<5>
The site in which the hemagglutinating agent is disposed in the lower member has an abundance per unit area of the hemagglutinating agent in a gap between the short grooves or in an overlapping portion overlapping the vicinity of the gap in the lateral direction, The absorbent article according to any one of <1> to <4>, wherein a portion of the lower member that does not overlap with the leak-proof groove is larger than an abundance per unit area of the hemagglutinating agent.

<6>
The absorbent article according to any one of <1> to <5>, wherein a weight average molecular weight of the hemagglutinating agent is 2,000 to 30,000,000.
<7>
The absorbent article according to any one of <1> to <6>, wherein the side leakage prevention groove includes a plurality of non-linear short grooves.
<8>
Any of the above <1> to <7>, wherein the plurality of non-linear short grooves have at least one curved portion that is convexly curved inward or outward in the lateral direction. 2. The absorbent article according to item 1.
<9>
Any of <1> to <8>, wherein a part or the entirety of the plurality of short grooves in the side leakage prevention groove has a shape curved convexly inward in the lateral direction. 2. The absorbent article according to item 1.
<10>
Any of <1> to <8>, wherein a part or the entirety of the plurality of short grooves in the side leakage prevention groove has a shape curved convexly outward in the lateral direction. 2. The absorbent article according to item 1.

<11>
<1> to <10>, wherein some or all of the plurality of short grooves forming the side leakage prevention grooves do not overlap in the width direction but overlap in the vertical direction. The absorbent article according to any one of the above.
<12>
The absorber has an absorbent core and a core wrap sheet covering the absorbent core,
The absorbent article according to any one of <1> to <11>, wherein the lower member containing the hemagglutinating agent is the absorbent core.
<13>
The absorber has an absorbent core and a core wrap sheet covering the absorbent core,
The core wrap sheet has a skin-side portion covering the skin-facing surface side of the absorbent core, and a non-skin portion covering the non-skin-facing surface side of the absorbent core,
The absorbent article according to any one of <1> to <12>, wherein the lower member containing the hemagglutinating agent is a non-skin portion of a core wrap sheet.
<14>
The absorption according to any one of <1> to <13>, wherein the hemagglutinating agent containing the hemagglutinating agent is contained over two or more of the lower members. Products.
<15>
The absorber has an absorbent core and a core wrap sheet covering the absorbent core,
The core wrap sheet has a skin-side portion covering the skin-facing surface side of the absorbent core, and a non-skin portion covering the non-skin-facing surface side of the absorbent core,
The lower member includes a skin side portion of the core wrap sheet, a non-skin portion of the absorbent core and the core wrap sheet,
The core wrap sheet has a skin-side portion covering the skin-facing surface side of the absorbent core, and a non-skin portion covering the non-skin-facing surface side of the absorbent core,
Any of the above <1> to <14>, wherein the hemagglutinating agent is disposed so as to cover any two or more of the skin side portion of the core wrap sheet, the absorbent core, and the non-skin portion of the core wrap sheet. 2. The absorbent article according to 1.

<16>
The absorber has an absorbent core and a core wrap sheet covering the absorbent core,
The core wrap sheet has a skin-side portion covering the skin-facing surface side of the absorbent core, and a non-skin portion covering the non-skin-facing surface side of the absorbent core,
The lower member includes a skin side portion of the core wrap sheet, the absorbent core and a skin side portion of the core wrap sheet,
The absorption according to any one of the above <1> to <15>, wherein the hemagglutinating agent is disposed so as to cover the entire skin side portion of the core wrap sheet, the absorbent core, and the non-skin portion of the core wrap sheet. Products.
<17>
The absorbent article according to any one of <1> to <16>, wherein the absorbent article is a sanitary napkin.

Hereinafter, the present invention will be described in more detail with reference to examples. However, the scope of the present invention is not limited at all by such examples.
[Example 1]
A sanitary napkin having the form shown in FIG. 1 was prepared and used as a sample of Example 1. An irregular nonwoven fabric having a basis weight of 30 g / m ² having ridges extending in the longitudinal direction X was used as the top sheet, and a moisture-permeable resin film was used as the back sheet. The thickness of the sanitary napkin was 4.2 mm. As the absorber 4, a mixed fiber (absorbent core) containing wood pulp fiber and a highly absorbent polymer is used. The mixed fiber is a thin paper having a basis weight of 16 g / m ² and a thickness of 0.3 mm. (Tissue paper) was used. In the mixed fiber, the basis weight of the wood pulp fiber was 300 g / m ² , and the basis weight of the superabsorbent polymer was 56 g / m ² . As the superabsorbent polymer, a general grade superabsorbent polymer for sanitary goods manufactured by Nippon Shokubai Co., Ltd. was used.

An aqueous solution prepared by dissolving 5 g of a hemagglutinating agent having the following formulation in 100 g of ion-exchanged water is prepared, and the solution is applied to the portion of the core wrap sheet covering the skin-facing surface of the absorbent core (skin-side core wrap sheet). Is impregnated by dropping into a portion disposed at a portion indicated by reference numeral 9, and then allowed to stand at 30 ° C. and 10% RH for 24 hours to be dried. Hemagglutination contained in the dried core wrap sheet What used the agent became 12 g / m < ² > was used.
(Prescription of hemagglutinating agent)
Unisense FPA1002L (Senka Corporation; polydiallyldimethylammonium chloride (weight average molecular weight: 600,000, 7856 meq / L)

[Example 2]
A 5% aqueous solution of a commercially available hemagglutinating agent is applied to a portion (skin-side core wrap sheet) of the core wrap sheet that covers the skin-facing surface of the absorbent core (the skin-side core wrap sheet) at a portion indicated by reference numeral 9A in FIG. A sanitary napkin was prepared in the same manner as in Example 1 except for drying, and this was used as a sample of Example 2.
[Example 3]
A sanitary napkin was prepared in the same manner as in Example 1 except that the amount of the hemagglutinating agent applied was changed to 50 g / m ² in terms of solid content, and this was used as a sample of Example 3.

[Comparative Example 1]
A sanitary napkin was prepared in the same manner as in Example 1 except that a hemagglutinating agent was not used, and a continuous annular leak-proof groove was formed over the entire circumference as the annular leak-proof groove. 1 sample.
[Comparative Example 2]
A sanitary napkin was prepared in the same manner as in Example 1 except that no hemagglutinating agent was used, and this was used as a sample of Comparative Example 2.

〔Evaluation test〕
The sanitary napkins of Examples and Comparative Examples were each evaluated for leakproofness and flexibility by the following methods. The results are shown in Table 1 below.

<Evaluation method of leakproofness>
Each sanitary napkin was fixed on a slope having an angle of 45 ° with respect to a horizontal plane, with the topsheet 2 side facing upward. In the excretion spot of the sanitary napkin in this state, 3 g of pseudo blood was dropped over 10 seconds. After standing for 3 minutes, the skin-facing surface of each napkin was observed, and it was visually observed whether or not the liquid had diffused beyond the leak-proof wall. If the liquid has not diffused beyond the leak-proof groove, 3 g of simulated blood is dropped again over 10 seconds, left for 3 minutes, and this operation is repeated until the liquid spreads beyond the leak-proof groove. The amount of simulated blood at the time when the liquid diffused beyond the groove was measured and evaluated according to the following criteria.
A: 12 g or more B: 6 g or more to less than 12 g C: less than 6 g The simulated blood was a B-type viscometer (manufactured by Toki Sangyo Co., Ltd., model number TVB-10M, measurement conditions: rotor No. The blood cell / plasma ratio of the defibrillated horse blood (manufactured by Nippon Biotest Laboratory Co., Ltd.) was adjusted so that the viscosity measured using a pressure of 19, 30 rpm, 25 ° C., and 60 seconds was 8 mPa · s. is there.

<Product flexibility sensory evaluation>
With the product invisible (put it in a box), ten monitors touch the product and evaluate the flexibility. The product of Comparative Example 1 was used as a criterion for flexibility. Compared to Comparative Example 1, the case of extremely flexible was 5, the case of flexible was 4, the same case was 3, the case of hard was 2, and the case of being very hard. A comparative evaluation is performed as 1. "A" indicates a case where the average value of these 10 persons is more than 4.0 and not more than 5.0, and "B" indicates a case where the average value is more than 3.5 and not more than 4.0. And the case where the value exceeds 3.5 and falls within the range of 3.5 or less is designated as “C”.

  As is clear from the results shown in Table 1, the sanitary napkin of Comparative Example 1 in which a continuous annular leak-proof groove was formed was excellent in leak-proof property, inferior in flexibility, and compared without using a hemagglutinating agent. The sanitary napkin of Example 2 has good flexibility but is inferior in leakproofness. On the other hand, it can be seen that the sanitary napkins of Examples 1 to 3, which are examples of the present invention, are excellent in both flexibility and leakproofness.

1,1A sanitary napkin (absorbent article)
2 Top sheet 3 Back sheet 4 Absorber 41 Absorbent core 42 Core wrap sheet 42a Skin side core wrap sheet (Core wrap sheet covering the skin facing side of the absorbent core)
Reference Signs List 5 Absorbent main body 6 Side leakage prevention sheet 7 Wing section 8 Annular leakage prevention groove 81 Side leakage prevention groove 81a Short front groove (short groove)
81b Central short groove (short groove)
81c Rear short groove (short groove)
81d Gap between short grooves 82 Front leak-proof groove 83 Rear leak-proof groove 9, 9A Coagulant disposition part A Front part B Excretion-facing part P Excretion spot part C Rear part

Claims (7)

A liquid-permeable top sheet that forms the skin-facing surface, a back sheet that forms the non-skin-facing surface, and an absorber disposed between these two sheets, a longitudinal direction along the front-back direction of the wearer and the longitudinal direction. An absorbent article for menstrual absorption having a transverse direction perpendicular to,
The skin-facing surface has side leakage-preventing grooves on both sides of a longitudinal center line, and the side leakage-preventing grooves are formed by a plurality of short grooves in which the topsheet is indented into the absorbent body. To have a gap, has a configuration arranged in the vertical direction,
The lower member disposed closer to the back sheet than the top sheet contains a hemagglutinating agent, and the gap in the side leakage prevention groove or the vicinity of the gap inside the gap in the lateral direction is the lower member. Overlaps with the site where the hemagglutinating agent is located,
The portion of the lower member where the hemagglutinating agent is disposed is the abundance per unit area of the hemagglutinating agent in the gap between the short grooves or in the overlapping portion overlapping the vicinity of the inside of the gap in the lateral direction, An absorbent article in which the amount of the hemagglutinating agent per unit area that does not overlap with the lateral leak-proof groove is larger than the amount present .   2. The absorbent article according to claim 1, wherein the absorbent article has a portion where the hemagglutinating agent is not disposed at a central portion in a lateral direction of the absorbent article.   The absorbent article according to claim 1, wherein the lower member is a member adjacent to the topsheet in a thickness direction of the absorbent article. The portion in which the hemagglutinating agent is disposed in the lower member has an abundance per unit area of the hemagglutinating agent in a gap between the short grooves or in an overlapping portion overlapping the vicinity of the inside of the gap in the lateral direction, 6 g / m ² or more and 80 g / m ² or less, the absorbent article according to any one of claims 1 to 3. The absorbent article according to any one of claims 1 to 4 , wherein the hemagglutinating agent has a weight average molecular weight of 2,000 to 30,000,000. The absorbent article according to any one of claims 1 to 5 , wherein the side leakage prevention groove includes a plurality of non-linear short grooves. The absorbent article according to claim 6 , wherein the plurality of non-linear short grooves have at least one curved portion that is convexly curved inward or outward in the lateral direction.

Images